Reaching HbA1c goals with saxagliptin in combination with other oral antidiabetic drugs

Postgraduate Medicine
James R LaSalle

Abstract

A large percentage of individuals with type 2 diabetes in the United States are not reaching their glycemic goals. In response to data from large outcomes trials and newer classes of therapeutic agents, various organizations and opinion-forming bodies recently updated their clinical practice recommendations for type 2 diabetes. The recommendations, as set by the American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD), the American Association of Clinical Endocrinologists/American College of Endocrinology, and the Canadian Diabetes Association, are similar in their emphasis on lifestyle modification and the importance of treating fasting and postprandial glucose, both of which are significant contributors to achieving glycated hemoglobin (HbA1c) targets. However, the recommendations differ in focus, depth, and specific treatment approaches. With the exception of the ADA/EASD consensus, dipeptidyl peptidase-4 (DPP-4) inhibitors have been included as alternative first- or second-line therapy due, in part, to their glucose-dependent mechanism of action that complements the actions of other oral antidiabetic drugs (OADs). The DPP-4 inhibitor, saxagliptin, demonstrates significant glycemia-lowering e...Continue Reading

References

Jun 26, 2001·Diabetes Care·P RaskinUNKNOWN Rosiglitazone Clinical Trials Study Group
Jun 11, 2003·Archives of Internal Medicine·John E Gerich
May 28, 2004·Pharmacotherapy·Mary T Korytkowski
Jan 19, 2005·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Denice S FeigUNKNOWN Canadian Task Force on Preventive Health Care
Dec 24, 2005·The New England Journal of Medicine·David M NathanUNKNOWN Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research
May 19, 2007·Diabetic Medicine : a Journal of the British Diabetic Association·A SchweizerS Dejager
Jul 12, 2007·JAMA : the Journal of the American Medical Association·Renee E AmoriAnastassios G Pittas
Oct 18, 2007·Current Opinion in Endocrinology, Diabetes, and Obesity·Julio Rosenstock, Bernard Zinman
Aug 30, 2008·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·B GökeS Dejager
Sep 12, 2008·The New England Journal of Medicine·Rury R HolmanH Andrew W Neil
Sep 17, 2008·The Review of Diabetic Studies : RDS·Richard E Pratley, Matthew Gilbert
Dec 3, 2008·Expert Opinion on Emerging Drugs·Bo Ahrén
Jan 6, 2009·Diabetes Care·UNKNOWN American Diabetes Association
Feb 24, 2009·Current Medical Research and Opinion·Debora Williams-HermanJohn M Amatruda
Apr 1, 2009·Postgraduate Medicine·Stephen Brunton
Aug 26, 2009·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·J E Foley, S Sreenan
Oct 28, 2009·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Helena W RodbardStanley S Schwartz
Oct 30, 2009·The Journal of Clinical Endocrinology and Metabolism·Priscilla HollanderUNKNOWN CV181-013 Investigators

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.